Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo

Cell Cycle

Volumn 11, Issue 13, 2012, Pages 2507-2517

  Carrassa, Laura ^a   Chilà, Rosaria ^a   Lupi, Monica ^a   Ricci, Francesca ^a   Celenza, Cinzia ^a   Mazzoletti, Marco ^a   Broggini, Massimo ^a   Damia, Giovanna ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Chk1; In vivo antitumor activity; Synthetic lethality; Targeted therapy; Wee1

Indexed keywords

CHECKPOINT KINASE 1; DNA; MK 1775; PF 00477736; PF 004777366; PROTEIN KINASE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN WEE1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DNA REPLICATION; DRUG RESISTANCE; FEMALE; GENETIC IDENTIFICATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; OVARY CANCER; PROSTATE CANCER; XENOGRAFT;

MUS;

EID: 84863799519     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20899     Document Type: Article

References (46)

1. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-9; PMID:11100718; http://dx.doi.org/10.1038/ 35044005.
2. Warmerdam DO, Kanaar R. Dealing with DNA damage: relationships between checkpoint and repair pathways. Mutat Res 2010; 704:2-11; PMID:20006736; http://dx.doi.org/10.1016/j.mrrev.2009.12.001.
3. 2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98:523-8; PMID:18231106; http://dx.doi.org/10.1038/sj.bjc.6604208.
4. 2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004; 3:513-9; PMID:15078995.
5. Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 2011; 10:4321-9; PMID:22134241; http://dx.doi.org/10.4161/cc.10.24.18661.
6. Stathis A, Oza A. Targeting Wee1-like protein kinase to treat cancer. Drug News Perspect 2010; 23:425-9; PMID:20862394.
7. Perry JA, Kornbluth S. Cdc25 and Wee1: analogous opposites? Cell Div 2007; 2:12; PMID:17480229; http://dx.doi.org/10.1186/1747-1028-2-12.
8. 2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277:1501-5; PMID:9278512; http://dx.doi.org/10.1126/science.277.5331.1501.
9. 2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997; 16:545-54; PMID:9034337; http://dx.doi.org/10.1093/emboj/16.3.545.
10. Lee J, Kumagai A, Dunphy WG. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol Biol Cell 2001; 12:551-63; PMID:11251070.
11. Dixon H, Norbury CJ. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 2002; 1:362-8; PMID:12548006; http://dx.doi.org/10.4161/cc.1.6.257.
12. Carrassa L, Broggini M, Erba E, Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 2004; 3:1177-81; PMID:15326376; http://dx.doi.org/10.4161/cc.3.9.1080.
13. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011; 17:88-96; PMID:21087899; http://dx.doi.org/10.1016/j.molmed.2010.10.009.
14. Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011; 10:2121-8; PMID:21610326; http://dx.doi.org/10.4161/cc.10.13.16398.
15. Merry C, Fu K, Wang J, Yeh IJ, Zhang Y. Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 2010; 9:279-83; PMID:20023404; http://dx.doi.org/10.4161/cc.9.2.10445.
16. Carrassa L, Sanchez Y, Erba E, Damia G. U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint. J Cell Mol Med 2009; 13:1565-76; PMID:19778378.
17. Syljuåsen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets and DNA breakage. Mol Cell Biol 2005; 25:3553-62; PMID:15831461; http://dx.doi.org/10.1128/MCB.25.9.3553-62. 2005.
18. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA 2011; 108:3336-41; PMID:21289283; http://dx.doi.org/10.1073/pnas.1012351108.
19. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009; 8:24; PMID:19371427; http://dx.doi.org/10.1186/1476-4598-8-24.
20. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 2010; 70:9693-702; PMID:21098704; http://dx.doi.org/10.1158/ 0008-5472.CAN-10-2286.
21. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012; 31:1661-72; PMID:21841818.
22. Höglund A, Nilsson LM, Muralidharan SV, Hasvold LA, Merta P, Rudelius M, et al. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res 2011; 17:7067-79; PMID:21933891; http://dx.doi.org/10.1158/1078-0432.CCR-11-1198.
23. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-98; PMID:16110319; http://dx.doi.org/10.1038/nrc1691.
24. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011; 17:2799-806; PMID:21389100; http://dx.doi.org/10.1158/ 1078-0432.CCR-10-2580.
25. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006; 26:7529-38; PMID:17015476; http://dx.doi.org/10.1128/MCB.00447-06.
26. Davies KD, Cable PL, Garrus JE, Sullivan FX, von Carlowitz I, Huerou YL, et al. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther 2011; 12:788-96; PMID:21892012; http://dx.doi.org/10.4161/cbt.12.9.17673.
27. De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, Würdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 2011; 17:4200-7; PMID:21562035; http://dx.doi.org/10.1158/1078-0432.CCR-10-2537.
28. Hawtin RE, Stockett DE, Wong OK, Lundin C, Helleday T, Fox JA. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget 2010; 1:606-19; PMID:21317456.
29. Baldin V, Ducommun B. Subcellular localisation of human wee1 kinase is regulated during the cell cycle. J Cell Sci 1995; 108:2425-32; PMID:7673359.
30. Peddibhotla S, Lam MH, Gonzalez-Rimbau M, Rosen JM. The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis. Proc Natl Acad Sci USA 2009; 106:5159-64; PMID:19289837; http://dx.doi.org/10.1073/pnas.0806671106.
31. Stumpff J, Duncan T, Homola E, Campbell SD, Su TT. Drosophila Wee1 kinase regulates CDK1 and mitotic entry during embryogenesis. Curr Biol 2004; 14:2143-8; PMID:15589158; http://dx.doi.org/10.1016/j.cub.2004.11.050.
32. Hoellein A, Pickhard A, von Keitz F, Schoeffmann S, Piontek G, Rudelius M, et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget 2011; 2:599-609; PMID:21865609.
33. Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 1995; 14:1878-91; PMID:7743995.
34. Sørensen CS, Syljuåsen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res 2012; 40:477-86; PMID:21937510; http://dx.doi.org/10.1093/nar/gkr697.
35. Beck H, Nähse V, Larsen MS, Groth P, Clancy T, Lees M, et al. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol 2010; 188:629-38; PMID:20194642; http://dx.doi.org/10.1083/jcb.200905059.
36. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y, et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010; 9:995-1004; PMID:20160494; http://dx.doi.org/10.4161/cc.9.5.10935.
37. 2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3:305-13; PMID:14726685; http://dx.doi.org/10.4161/cbt.3. 3.697.
38. Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, Laursen H, et al. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 2010; 29:5095-102; PMID:20581868; http://dx.doi.org/10.1038/onc.2010.249.
39. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352-5; PMID:18323444; http://dx.doi.org/10.1126/science.1140735.
40. Backert S, Gelos M, Kobalz U, Hanski ML, Böhm C, Mann B, et al. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int J Cancer1 999; 82:868-74; PMID:10446455; http://dx.doi.org/10. 1002/(SICI)1097-0215(19990909)82:6〈868::AID-IJC16〉3.0.CO;2-W.
41. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004; 15:252-6; PMID:14760118; http://dx.doi.org/10.1093/annonc/mdh073.
42. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S, et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA 2011; 108:4908-13; PMID:21383199; http://dx.doi.org/10.1073/pnas.1101795108.
43. Butz H, Likó I, Czirják S, Igaz P, Khan MM, Zivkovic V, et al. Downregulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J Clin Endocrinol Metab 2010; 95:181-91; PMID:20668041; http://dx.doi.org/10.1210/jc.2010-0581.
44. Vikhanskaya F, Colella G, Valenti M, Parodi S, D'Incalci M, Broggini M. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin Cancer Res 1999; 5:937-41; PMID:10213232.
45. Kittler R, Putz G, Pelletier L, Poser I, Heninger AK, Drechsel D, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 2004; 432:1036-40; PMID:15616564; http://dx.doi.org/10.1038/nature03159.
46. Lupi M, Cappella P, Matera G, Natoli C, Ubezio P. Interpreting cell cycle effects of drugs: the case of melphalan. Cancer Chemother Pharmacol 2006; 57:443-57; PMID:16195878; http://dx.doi.org/10.1007/s00280-005-0044-1.